It is reported that Jingfeng Medical, a surgical robot platform company, recently announced the completion of a round C financing contract of more than 200 million US dollars. This round of financing is led by Boyu Investment, jointly led by Temasek and Sequoia Capital China, additional investment by old shareholders such as Sanzheng Health Investment, LYFE Capital (Continental Capital) and National Policy Investment, and investors such as mixed ownership Reform Fund of Chinese State-owned Enterprises, OrbiMed, Morning one Investment, Greater Bay area Fund, Octagon Capital, Sage Partners, Lingang Blue Bay Capital, Future assets and so on. Dr. Wang Jianchen, founder of Jingfeng Medical, said that this round of funds will help the overall improvement of the company's business and the rapid commercialization of its core products, such as the deep expansion of product research and development, the construction of large-scale production bases and training centers, and a comprehensive commercial layout.
Jingfeng Medical is an intelligent surgery system developer founded in 2017 by two PhDs who have studied at MIT and Harvard University in the United States. According to reports, the company is the only one in China and the second company in the world to master single-hole surgery robot and porous surgery robot technology at the same time. At present, it already has three major product pipelines centered on robot technology, including the most widely used porous laparoscopic surgery robot system, the single-hole laparoscopic surgery robot system representing the development direction of surgery, and ultra-high-definition stereoscopic endoscope. Focusing on many core technologies such as structural design, system control, motion algorithm and artificial intelligence algorithm involved in surgical robot, Jingfeng Medical has applied for more than 400 patents at home and abroad.
The company's porous surgical robot completed urology registration in September 2021. The clinical trial was jointly conducted by the General Hospital of the Chinese people's Liberation Army, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Cancer Prevention and treatment Center of Sun Yat-sen University and the first affiliated Hospital of Zhengzhou University. At the same time, the robot first entered the stage of registered clinical trials in the gynecology field in August this year, becoming the first endoscopic surgery robot system in China to enter dual-department clinical trials. In addition, the special application for "innovative medical devices" of Jingfeng single-hole surgical robot was approved in April 2021 and is about to enter the stage of registered clinical trials.
Cao Yanling, investment partner of Boyu, said: "Robot assisted surgery (RAS) is a milestone in the development of clinical surgery. Compared with open surgery and traditional minimally invasive surgery, RAS has the advantages of flexibility and accuracy, anti-fatigue radiation, large and clear field of vision, small wound recovery, less bleeding and less complications. It has significant clinical value in many difficult operations. It has a broad development prospect in the global surgery market. "
Sequoia Capital China said that at present, domestic surgical robots rely on imports to meet clinical needs. Intuitive Surgical of the United States, which accounts for the largest market for surgical robots in the world, sells Leonardo da Vinci surgical robots for about 30 million yuan in China, according to Frost&Sullivan. The emergence of domestic surgical robots in Jingfeng Medical is expected to reduce this cost and benefit patients, doctors and hospitals.
Editor: Tang Yuting
Expand reading:
Continue to promote the surgical robot business, "Jingfeng Medical" completed nearly 600 million yuan B round financing
Focus on minimally invasive surgery platform products, "Jingfeng Medical" completed more than 100 million yuan Pre-B round financing